A non-opioid painkiller developed by Pfizer Inc. and Eli Lilly and Co. succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed.
Pfizer Inc. forecast 2019 profit and sales below Wall Street estimates as the company expects to take a blow from a stronger dollar and as well as the loss of patent on the blockbuster pain treatment Lyrica during 2019.
Here is a look at BioSpace’s top 10 stories of 2018.
Tanezumab, a non-opioid drug developed by Pfizer and Eli Lilly, met the main goals of a late-stage study in which over half of patients reported a significant reduction in hip or knee osteoarthritis pain.
The U.S. Food and Drug Administration’s Anesthetic and Analgesic Drug Products Advisory Committee voted to recommend AcelRx Pharmaceuticals’ Dsuvia to manage moderate-to-severe pain.
Shares of Pacira Pharmaceuticals plunged more than 15 percent after the company revealed a U.S. Food and Drug Administration advisory panel recommended against approving expanded use of the company’s pain treatment Exparel.
Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros ($88 million), in a deal which Ipsen said should boost its profits.